Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 42, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies.
Editor's Note: The "Qiming Weekly" column is published regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take is worth recording. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and join you in marking the milestone moments of our portfolio companies.
ESG
01/
Qiming Venture Partners and Multiple Portfolio Companies Support Hong Kong Disaster Relief
A level-five fire broke out on the afternoon of November 26 in multiple residential buildings at Wang Fu Court, Tai Po Estate, in Hong Kong's New Territories, causing significant casualties and drawing widespread concern. To support affected residents through the crisis and facilitate post-disaster reconstruction, Qiming Venture Partners and several of its portfolio companies responded swiftly, making generous donations of funds and supplies to fulfill their corporate social responsibility through concrete action.
Qiming Venture Partners has donated HK$3 million to the "Tai Po Wang Fu Court Relief Fund" established by the Hong Kong SAR Government. The firm extends its deepest condolences to families affected by this major fire, and expresses its highest respect to the firefighters and rescue personnel battling on the front lines, thanking them for their professional dedication and selfless sacrifice in this time of crisis. Qiming Venture Partners hopes this donation will help alleviate the difficulties facing affected residents and assist them in returning to normal life as soon as possible; the firm also calls on more social forces to join in the effort to achieve genuine community reconstruction.
Additionally, multiple Qiming portfolio companies have joined forces to support search and rescue operations, injured treatment, and post-disaster reconstruction: the Xiaomi Foundation in Hong Kong urgently contributed HK$10 million for medical aid to affected residents and emergency transitional living assistance; Meituan's food delivery platform Keeta announced an emergency donation of HK$5 million to support transitional housing, daily necessities, and community recovery efforts for affected residents; Tuhu Car launched a donation of HK$3 million to support fire rescue operations, transitional housing, living supplies, and reconstruction for affected residents; UBTECH donated HK$1 million and small humanoid companion robots worth HK$500,000 to support Hong Kong fire rescue and reconstruction efforts, providing companionship and assistance to elderly and children; and CloudMinds urgently initiated donation procedures, contributing HK$500,000 specifically for emergency rescue, transitional housing, and basic living supplies for affected residents.
Funding News
Infinigence AI Completes Nearly RMB 500 Million Series A+ Round
Deepening Agentic Infra Layout for the Agent Era
Recently, Qiming Venture Partners portfolio company Infinigence AI completed a nearly RMB 500 million Series A+ funding round. This round brought together national industrial capital and leading market-oriented funds — dual recognition from "state capital + market" that affirms the company's technological innovation addressing major national strategic needs while strongly encouraging Infinigence AI to continue solidifying its value creation in AI industry deployment and infrastructure ecosystem building.
Since its founding two and a half years ago, Infinigence AI has consistently built high-performance AI infrastructure for the cutting edge of artificial intelligence technology and application deployment. Through software-hardware co-optimization and heterogeneous computing services, the company has developed the "Infinigence AI Cloud" and "Boundless Edge Intelligence Solutions" for AI development and services, breaking through computing bottlenecks constraining AI industry applications. It already serves leading AI and agent companies including Baichuan, Moonshot AI, Lenovo Capital and Incubator Group, Liepin, Li Auto, Lovart, Sand.ai, Shengshu Technology, Soul, VAST, H3C, Zhipu AI, China Mobile, and ZTE terminals, as well as AI research institutions including Beijing Zhongguancun Academy, Shanghai Artificial Intelligence Laboratory, Shanghai Algorithm Innovation Research Institute, Zhejiang Lab, and BAAI — helping each unlock the intelligent potential of every unit of computing power.
Dr. Lixue Xia, co-founder and CEO of Infinigence AI, stated: "The paradigm shift of Agentic AI represents not only a strategic opportunity but a mission entrusted to us by the era. Thanks to our technical expertise and engineering capabilities accumulated over years in AI systems, Infinigence AI has nimbly completed its transformation to agent-native infrastructure. The completion of this new funding round will inject even stronger momentum into our development. Facing the agent era, Infinigence AI will continue to rely on software-hardware co-optimization as its technical foundation, with building a new generation of learnable, evolvable Agentic Infra as its strategic core — producing agents, collaborating with agents, and serving agents (Into Agent, With Agent, For Agent) — to achieve deeper breakthroughs in AI infrastructure system optimization and ecosystem building."
Major Partnerships
01/
Gan & Lee Pharmaceuticals Exclusively Licenses Bofangelutide to Leading Latin American Pharmaceutical Company PC
Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) has officially announced an exclusive licensing and commercial supply agreement with Productos Científicos S.A. de C.V. (hereinafter "PC"), a well-known pharmaceutical enterprise in Latin America, for bofangelutide (development code: GZR18) — the world's most advanced glucagon-like peptide-1 receptor agonist (GLP-1RA) biweekly formulation, independently developed by Gan & Lee.
Under the agreement terms, Gan & Lee has granted PC exclusive rights to develop and commercialize bofangelutide injection in Latin America (including key countries such as Mexico and Brazil) for a fee, launching an entirely new commercialization layout for Gan & Lee's innovative drug bofangelutide in the region.
Gan & Lee Chief Commercial Officer Kai Du and Key Account Director Dr. Dhaval Soneji jointly stated that this strategic partnership with PC marks a new phase in the company's business expansion in the Latin American market. Both parties agree that this cooperation not only further consolidates the company's localized presence in the region, but also represents the first international export of an independently innovated drug — successfully bringing an original product centered on clinical value to overseas markets and achieving synchronized global R&D and launch of innovative drugs. As a pharmaceutical enterprise with long-term commitment to internationalization, Gan & Lee has consistently pursued a dual-driven "Innovation + Globalization" strategy. This successful first step in innovative drug "going global" validates the foresight of the company's years of high R&D investment, while also laying the foundation for subsequent pipeline products to enter more overseas markets.
PC Chairman Guy Jean Savoir and CEO Edmundo Jimenez stated: The partnership with Gan & Lee is an important step in advancing metabolic disease management in Latin America. Through this cooperation, PC will accelerate the regulatory advancement of bofangelutide injection, enabling it to deliver tangible public health value in a region where the burden of metabolic diseases is growing rapidly — benefiting patients, healthcare providers, and the entire Latin American healthcare system.
02/
Tianyu Technology's First Biologics Pipeline Partnership Reaches Overseas
Recently, Qiming Venture Partners portfolio company Tianyu Technology reached an innovative biologics pipeline cooperation agreement with a leading global American biotechnology company founded by top entrepreneurs in the life sciences field. Under the agreement, Tianyu Technology will be entitled to commercial returns including development upfront payments, development milestones, and product commercialization revenue, as well as additional potential licensing income. This partnership not only marks Tianyu Technology's formal entry into the global strategic market, but also signals that AI technology is comprehensively driving biologics R&D into a new stage.
Tianyu Technology's core technical engine is its leading AI protein design platform, AIACCLBIO®. Built on VenusPod, the world's largest protein sequence dataset for pre-training, the platform integrates core capabilities including AI-directed evolution, enzyme mining, and de novo design. It has already amassed extensive success stories in enhancing protein performance — particularly extreme tolerance to high temperatures, strong acids, and strong bases. These capabilities demonstrate the platform's broad application potential across biopharmaceuticals, industrial enzyme design, environmental catalysis, and biosynthesis. This partnership serves as powerful validation of its exceptional ability to achieve efficient design in complex biopharmaceutical scenarios.
Liu Hao, CTO of Tianyu Technology, stated: "This collaboration with our international partner goes beyond simple technical recognition. It symbolizes our shared vision for 'AI-driven innovation in biopharmaceuticals.' This not only confirms AIACCLBIO®'s ability to solve real-world drug discovery challenges, but more importantly, it establishes Tianyu Technology's role as an innovation engine, jointly advancing highly challenging R&D pipelines."
03/
WeRide and Uber Launch Fully Driverless Robotaxi Commercial Operations in Abu Dhabi
Recently, Qiming Venture Partners portfolio company and global leading autonomous driving technology company WeRide (NASDAQ: WRD, 00800.HK) and international mobility service giant Uber (NYSE: UBER) announced the official launch of L4 fully driverless Robotaxi commercial operations in Abu Dhabi. This marks the first deployment of fully driverless Robotaxi operations in the Middle East, and Abu Dhabi becomes the first city globally outside the United States to offer fully driverless Robotaxi services on the Uber platform. This commercial deployment is supported by the first city-level fully driverless Robotaxi operating license issued outside the United States globally.
This milestone marks a critical step for the UAE in large-scale deployment of autonomous mobility solutions, made possible through the continued collaboration between WeRide, Uber, the Abu Dhabi Integrated Transport Centre (ITC), and fleet operator Tawasul.
Effective immediately, public-facing fully driverless Robotaxi commercial operations will first launch on Yas Island, with no safety operator in the vehicle. Passengers can be matched with a WeRide Robotaxi through Uber X or Uber Comfort, or directly hail one through the newly launched "Autonomous" dedicated category — the first autonomous driving-exclusive option Uber has rolled out globally.
04/
UBTECH and Zhuoshi Technology Enter Strategic Partnership
Recently, Qiming Venture Partners portfolio company UBTECH (9880.HK) and Zhuoshi Technology formally signed a strategic cooperation framework agreement in Shenzhen. The collaboration will focus on the core direction of "industry-specific models + Embodied Artificial Intelligence," jointly promoting the deployment of industry large models + humanoid robots across multiple sectors. The two parties plan to deploy 10,000 robots and jointly expand billions in commercial orders within the next five years — a first in the industry — signaling that their partnership has already moved beyond the "proof of concept" stage and directly into commercial deployment of "large models + robots."
As the first humanoid robot stock, UBTECH has built full-stack humanoid robot technical capabilities. Its 2025 humanoid robot order volume has already reached 1.3 billion yuan, continuing to lead global breakthroughs in humanoid robot core technology and commercialization. Zhuoshi Technology is a leading innovative enterprise in AI industry large models and intelligent applications, with a core team drawn from top AI ranks, possessing leading capabilities in large model algorithms, data governance, and commercial deployment of intelligent agents and terminal products.
The two parties will advance cooperation across five dimensions: joint R&D, scenario application deployment, industrial ecosystem collaboration, capital cooperation, and business development and joint innovation. They plan to co-build a joint research laboratory focused on the "industry-specific models + Embodied Artificial Intelligence" direction, prioritizing breakthroughs in four domains: industrial manufacturing, enterprise services, healthcare and wellness, and cultural education and media. They will design feasible solutions for real-world scenarios, build industrial empowerment platforms and Embodied Artificial Intelligence empowerment centers, and accelerate the industrialization of AI technology across multiple regions and industries.
R&D Progress
01/
Belief BioMed's BBM-C101 Gene Therapy for Cervical HSIL Receives China IND Approval
Recently, Qiming Venture Partners portfolio company Belief BioMed, an innovative enterprise focused on cutting-edge gene therapy, announced that the clinical trial application (IND) for its gene therapy drug BBM-C101 injection for cervical high-grade squamous intraepithelial lesion (HSIL) has been approved by the National Medical Products Administration (NMPA).
Dr. Xiao Xiao, co-founder, chairman, and chief scientific officer of Belief BioMed, stated: "In this golden autumn season of abundant harvest, we share with joy and honor the good news that BBM-C101 injection's clinical trial application has been approved in China. We sincerely thank the NMPA for its efficient review of this IND application, and also thank the Belief team for its unremitting efforts and dedication. Going forward, we will fully advance the clinical research process, striving to provide this novel gene therapy option for HSIL treatment at the earliest opportunity."
This clinical trial is an open-label, multiple-dose study designed to evaluate the safety, tolerability, and efficacy of subcutaneous BBM-C101 injection in female patients aged 18-45 with confirmed HPV16 and/or HPV18 infection-related HSIL. BBM-C101 uses a non-replicating recombinant adenovirus (rAd) as a vector, which can co-express HPV antigens and immune activation factors in host cells, potentially offering a gene therapy option for patients with HPV16 and/or HPV18-related HSIL.
02/
Gan & Lee Pharmaceuticals Initiates China's First Monthly-Dosing GLP-1RA Phase III Weight Loss Study, GRADUAL-3
Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) announced that its self-developed glucagon-like peptide-1 receptor agonist (GLP-1RA) bofanglutide (development code: GZR18) injection has officially initiated a Phase III clinical trial (GRADUAL-3) for the obesity or overweight indication. This is the third large-scale Phase III clinical study for bofanglutide in the obesity/overweight field. The study will employ a once-every-four-weeks subcutaneous injection monthly formulation regimen, aiming to explore the clinical potential of bofanglutide injection in weight control and maintenance.
This study (Clinical Trial Registration and Information Disclosure Platform: CTR20254659) aims to explore the effect and safety of bofanglutide injection on body weight after 24 weeks of continuous treatment with once-monthly dosing. The study is led by principal investigator Professor Ji Linong of Peking University People's Hospital, with the primary endpoints being the change in body weight from baseline and percentage change after 24 weeks of treatment.
Previously, for the obesity or overweight indication, Gan & Lee Pharmaceuticals had already initiated two Phase III clinical studies (GRADUAL-1 and GRADUAL-2). In the GRADUAL-2 study, bofanglutide injection became the first GLP-1RA globally to conduct a head-to-head parallel controlled study against Wegovy® (Semaglutide 2.4mg) in Chinese adults with obesity/overweight with or without type 2 diabetes, aiming to comprehensively evaluate and validate the efficacy and safety of bofanglutide injection in patients with obesity or overweight, and assess its comprehensive improvement capabilities for different metabolic indicators and cardiovascular risk factors. The Phase III clinical study initiated this time (GRADUAL-3) will further explore the potential of bofanglutide injection for weight control and maintenance with once-monthly dosing, aiming to improve patient medication adherence through lower injection frequency and more convenient treatment methods, and address the current challenges of weight rebound and suboptimal efficacy with long-term GLP-1RA therapy.
03/
Insilico Medicine Nominates CBLB Inhibitor ISM3830 for Advanced Tumor Immunotherapy
Recently, Qiming Venture Partners portfolio company Insilico Medicine, a clinical-stage biotech company powered by generative artificial intelligence, Insilico Medicine today announced the nomination of ISM3830, a potential best-in-class, oral, highly selective CBLB inhibitor with an AI-enabled novel scaffold, as a preclinical candidate compound targeting treatment of multiple advanced tumors.
Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, said: "From PCC nomination to positive clinical results, reproducible real-world validation has strengthened our conviction that AI's transformative potential in drug development lies not only in accelerating efficiency, but in enabling genuine therapeutic innovation. Moreover, the underlying mechanism of CBLB inhibition can address indications with low response rates or acquired resistance to immune checkpoint inhibitors — an area of massive unmet need today. We look forward to combining AI-driven efficiency with human expertise to break through this industry bottleneck."
04/
Qiming Venture Partners Portfolio Company Wuso Medical Granted US Patent for Cardiac Conduction System Pacing Invention
Recently, Wuso Medical, a Qiming Venture Partners portfolio company, was granted a US invention patent by the United States Patent and Trademark Office (USPTO) for its self-developed "Catheter and Leads for Cardiac Conduction System," patent number US 12,458,797 B2.
This milestone achievement not only marks further refinement of Wuso Medical's foundational core technology layout in physiological pacing, but also confirms our solid progress on the global medical device original innovation track.
Product Launches
01/
UBTECH Releases New Meng UU Family Product "Youzai"
Recently, UBTECH (9880.HK), a Qiming Venture Partners portfolio company, officially launched the newest addition to its Meng UU family — "Youzai." Pre-orders opened December 1 on the Tmall Meng UU flagship store and the UBTECH Smart Robot Douyin livestream room, with a limited first batch of 2,000 units.
Since debuting the Meng UU family's first product "Mengzai" in June 2025, the Meng UU companion robot has introduced a series of groundbreaking designs for "digital life interactive experiences." Its pioneering features include the "digital personality blind box," "cloud travel," "digital wardrobe dressing," and "CPDD social walkie-talkie" — nurturing-style gameplay combined with adorable facial expressions, customizable outfits, polished app interfaces, and a growth-oriented robot brain with long-term memory. Together these build a comprehensive cyber-emotional companionship system that has proven wildly popular among Gen Z users, topping Douyin's smart robot category sales in October of the same year.
The upcoming "Youzai" builds on this established systematic foundation, achieving comprehensive evolution across life form, artistic design, interactive experience, and gameplay: personality-imbued life forms, individualized color-driven artistic design, full-scenario conversational interaction, and enduring nurturing-style gameplay.
As UBTECH's frontier explorer in emotional intelligence, the Meng UU series not only provides users with "warm companionship" — the technology and capabilities it develops will further empower diverse product forms including the desktop robot AI Wukong and humanoid robot Walker, building unified "personality systems" and "emotional models." Combined with real-machine training data from industrial scenarios, UBTECH is steadily advancing toward its vision of emotional embodied intelligence where "the body (hardware) is replaceable, the soul is cumulative."
02/ Shengshu Technology Upgrades Vidu Q2 Reference-to-Image Feature
Recently, Shengshu Technology, a Qiming Venture Partners portfolio company, announced upgrades to Vidu Q2's reference-to-image feature, alongside newly launched text-to-image and image editing functions. This completely breaks the dilemma where AI multimodality couldn't simultaneously deliver creativity and controllability, returning full creative control to creators.
Vidu Q2 image generation offers exceptional consistency. Its signature reference-to-image feature has been upgraded, while text-to-image and image editing functions are newly available with stunning consistency results, ready for direct deployment in commercial scenarios including short-form dramas and animation, advertising and e-commerce, interactive entertainment, film and television, and cultural tourism and education. The workflow from reference-to-image to subject preservation to reference-to-video eliminates frequent platform switching, enabling a one-stop pipeline. Inspiration needs no waiting — fastest output in 5 seconds, with efficiency more than doubled. Members enjoy up to one month of free access to text-to-image, reference-to-image, and image editing functions; flagship members get unlimited free generation.
Notably, in the latest global image editing rankings published by international authoritative AI benchmarking organization Artificial Analysis, Vidu's image editing function ranked in the top four upon its debut, surpassing OpenAI's GPT-5 and matching Nano Banana2, becoming the only startup in the top four. This marks Vidu Q2's internationally leading consistency and technical maturity in image editing.
Building on this foundation, Vidu has completed construction of a multimodal product matrix spanning video generation, audio generation, image generation, and image editing, achieving end-to-end full-stack self-developed technical closure. This layout not only builds an efficient, coherent one-stop AI creation workflow for creators, but also gradually forms the company's sustainable evolving technical moat and system-level competitiveness in the AI multimodal domain.
Technology & Expertise
01/
2025 Yao Medical International Health Forum Successfully Held
Recently, Yao Medical, a Qiming Venture Partners portfolio company, successfully held its International Health Forum in Shanghai themed "International Healthcare • China Innovation." The forum invited renowned domestic and international medical experts, as well as entrepreneurs and senior executives from technology, finance, education, and other sectors, for insightful sharing and dialogue on new trends and innovative practices in global health development.
The full-day forum featured three parallel sub-forums: the CAR-T Therapy and Hematologic Tumor Treatment Progress Forum, the "Her Health" Women's Health International Forum, and the New Horizons in Medical Service and Innovation Models Forum. Through keynote speeches and roundtable discussions, covering frontier hematologic tumor treatments to whole-lifecycle women's health protection, from cross-domain AI applications to longevity medicine exploration, the 2025 Yao Medical International Health Forum built an international exchange platform that will effectively promote deep integration of global frontier medical wisdom with Chinese clinical practice.
Dr. Haoying Shi, Founder and CEO of Yao Medical, emphasized: "'International Healthcare · China Innovation' is not a slogan, but the development path Yao Medical has consistently adhered to. Yao Medical is committed to gathering the world's top medical resources and bringing the most cutting-edge global medical wisdom in; at the same time, we combine international experience with local realities, exploring locally innovative medical service models in practice, demonstrating China's implementation speed and model innovation."
02/
Axera Semiconductor Appears at IC China 2025
The 22nd China International Semiconductor Expo (IC China 2025) was successfully held November 23-25 at the Beijing National Convention Center. At the "Artificial Intelligence and Large Model Chip Forum," Axera Semiconductor, a Qiming Venture Partners portfolio company, saw its Co-founder and Vice President Jianwei Liu invited to deliver a keynote speech titled "AI Processors: Accelerating Edge Infrastructure Intelligence," sharing the company's practices and perspectives in edge-side and end-side AI chips.
Liu said AI not only enables more intelligent experiences, but represents "a stable, reliable intelligence foundation — as fundamental as water and electricity." Especially since the rise of large model technology, AI has enabled the large-scale replication of human experience and knowledge, transforming processes that once relied on human judgment into standardized industrial products. This dramatically boosts productivity, drives intelligent upgrading across thousands of industries, and amounts to a cost-driven productivity revolution.
Faced with such widespread AI applications, how should we build the computing infrastructure to match? Axera found its answer in the evolution of computing architectures. Just as GPUs diverged from CPUs due to graphics computing demands, today's AI applications have made general-purpose processors suboptimal in energy efficiency and cost-effectiveness. Therefore, designing dedicated processing architectures for AI has become key to scaling edge and end-side intelligence.
Axera's proposed solution is a dedicated AI processor architecture combining "operator instruction sets with dataflow DSA microarchitecture." This architecture treats AI programs as computational graph structures, designing common operators directly as processor execution instructions — enabling more efficient hardware-level support for high-dimensional tensor data flow and computation. Compared to traditional GPU architectures, this design dramatically reduces the power consumption and latency from data movement, concentrating more resources on effective computation, significantly improving energy efficiency and cost-effectiveness, and proving more environmentally friendly.
03/
CIX Technology 2025 Ecosystem Conference: Co-Creating an Open, Intelligent Future
Recently, CIX Technology's 2025 Ecosystem Conference, themed "Everything Connected by Chips, Endlessly Alive," was held in Shanghai. Qiming Venture Partners portfolio company CIX Technology joined hands with global ecosystem partners and industry customers including Arm, Lenovo, and Baidu to focus on hot topics such as AI PCs, Embodied Artificial Intelligence, large models, and edge AI — confronting market opportunities and challenges together to build an open, mutually beneficial intelligent ecosystem.
In his opening address, CIX Technology Founder and CEO Wenjian Sun stated that from its founding, CIX Technology has firmly committed to the path of "one chip, many uses" — dedicated to building a general-purpose intelligent computing foundation that empowers thousands of industries and adapts to countless scenarios. The CIX P1 and future products aim to provide partners with the most reliable, most efficient end-side computing engines as AI becomes ubiquitous. CIX Technology will uphold an ecosystem-building philosophy of openness, empowerment, and symbiosis, working in deep collaboration with leading global partners to create a full-stack innovation environment from chips to models, from OS to applications, plus an open development environment — jointly defining products, exploring markets, and creating value to build a thriving end-side AI ecosystem together.
Sun revealed that in 2026, CIX Technology will introduce a new generation of products with stronger computing power, higher energy efficiency ratios, and better alignment with next-generation end-side AI device requirements — building more competitive next-generation solutions to deliver more powerful, more efficient user experiences.
04/
HyperStrong Successfully Delivers 420+ MWh Energy Storage Project in the United States
Recently, Qiming Venture Partners portfolio company HyperStrong (688411.SH) officially announced that its US subsidiary reached energy storage project cooperation agreements with multiple enterprises including a well-known US independent power producer (IPP) this September. The company will provide energy storage system solutions for energy storage power station projects located in California and Georgia, along with long-term warranty services and full-lifecycle after-sales support. As of the reporting date, all supplied products for the projects have been delivered on schedule, totaling over 420 MWh. The successful fulfillment of this cooperation project marks HyperStrong's key breakthrough in the US market, representing an important milestone in the company's internationalization strategy for the Americas region.
This cooperation project deploys HyperStrong's HyperBlock III 5 MWh liquid-cooled energy storage system. After commissioning, it will focus on the energy dispatch needs of grid-scale energy storage stations, providing efficient peak shaving and valley filling, frequency regulation, and peak regulation services — helping alleviate local grid supply-demand fluctuations, optimizing regional renewable energy consumption efficiency, and ensuring power supply for nearly 20,000 households daily. After the project enters commercial operation, HyperStrong will continue providing long-term warranties and comprehensive localized after-sales services. Through full-lifecycle system monitoring, routine maintenance and inspection, and other measures, the company will ensure continuously optimized equipment performance, fully guarantee stable and efficient project operation, and maximize project application value.
05/ Tigermed Appears at Boao Dual Conferences
Recently, the "First Global Innovative Drug and Device Expo" and the "Fourth Boao International Real-World Study Conference for Drugs and Devices" were held over three consecutive days, bringing together government representatives, university experts, research institutes, pharmaceutical and device enterprises, and industry practitioners from home and abroad to discuss the latest advances in drug and device regulatory science and real-world studies, promoting global health development.
Qiming Venture Partners portfolio company Tigermed (300347.SZ, 03347.HK) President Xiaochun Cao led Tigermed's clinical operations department and subsidiary Tigermed Yitan to participate in both major events, engaging in in-depth discussions with industry peers. With integrated professional capabilities and forward-looking industry vision, Tigermed is helping advance the globalization of innovative drugs and devices and the development of real-world study fields.
From helping innovative drugs and devices "set sail overseas" to safeguarding drug safety across the full lifecycle, from participating in Lecheng policy implementation to promoting global real-world study standard coordination — Tigermed took the Boao dual conferences as an opportunity to further deepen cooperation and communication with all parties in the industry. Going forward, as the Hainan Free Trade Port begins independent customs operations and Lecheng's "Four Major Platforms" construction advances, Tigermed will continue working hand-in-hand with Lecheng to facilitate the transformation of global innovative drug and device achievements, bringing more new drugs, new technologies, and new devices to benefit patients. The company will also continue focusing on industry needs, upgrading service and technical capabilities, and driving innovation and development in the healthcare industry.
Corporate Honors
01/
Axera's Edge Computing AI Chip Axera-Xi Series Wins 2025 World Electronics Achievement Award
Recently, at the "2025 World Electronics Achievement Awards" ceremony hosted by AspenCore, Qiming Venture Partners portfolio company Axera won the "Innovative Product of the Year" award for its edge computing AI chip — the "Axera-Xi" series.
This series of AI SoCs features high energy efficiency, low power consumption, and high intelligence-to-cost ratio advantages. Based on the company's self-developed "Axera Tongyuan mixed-precision NPU" core IP technology, it focuses on enhancing mission-critical processing capabilities and optimizing memory usage efficiency, with deep optimization specifically for neural network fundamental operations and tensor computing. This design not only ensures consistently stable low-latency performance, but enables complex AI models to run efficiently under the strict power constraints of edge devices. The World Electronics Achievement Awards aim to recognize enterprises, managers, and products that have made outstanding contributions to global electronics industry innovation, and have enjoyed broad influence and authoritative recognition in the industry for many years.
02/
CIX Technology Named to 2025 openKylin Community Annual Technical Contribution Awards List
The 2025 OpenAtom Developer Conference — openKylin AI Technology Forum and Technical Committee was successfully held in Beijing. At the conference, the 2025 openKylin Community Annual Technical Contributor Awards ceremony was grandly held, with the "openKylin Arm version CIX feature integration" project receiving the openKylin Annual Most Influential Project award.
This openKylin Community Annual Technical Contribution Awards selection aims to honor outstanding contributors who have actively driven community technological innovation over the past year. At the conference, over 20 excellent projects and 50 outstanding developers received recognition. The awarded projects and individuals have set benchmarks in technological innovation and community contribution.
CIX Technology was recognized with the openKylin Annual Most Influential Project for its deep contribution in successfully integrating its self-developed CIX P1 chip Linux kernel code into the openKylin community kernel mainline. Following rigorous community review and testing, the integrated code totaled up to 117,000 lines, comprehensively covering the CIX P1's core functional modules and building a complete, efficient software driver system.
Previous Highlights
Qiming Weekly | Qiming Venture Partners Portfolio Updates Vol. 41, 2025 Qiming Honors | Qiming Venture Partners and 10+ Portfolio Companies Named to Diyixinsheng's 3rd AI Innovation Pioneers — 2025 China AI Industry Innovation Pioneer List
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on exchanges including the NYSE, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), AusperBio, Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.